Xencor Stock Gains 23% on Encouraging Pipeline Advancements

Zacks09-11

Shares of Xencor XNCR gained 23% on Monday after it revealed details on four new programs targeting autoimmune diseases and provided encouraging initial updates on two early-stage oncology programs. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466746258?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","is_english":true,"pubTime":"2024-09-11 00:22","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2466746258","market":"us","top_or_hot":-1,"title":"Xencor Stock Gains 23% on Encouraging Pipeline Advancements","media":"Zacks","content":"<div>\n<p>Shares of Xencor XNCR gained 23% on Monday after it revealed details on four new programs targeting autoimmune diseases and provided encouraging initial updates on two early-stage oncology programs.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/xencor-stock-gains-23-encouraging-162200053.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xencor Stock Gains 23% on Encouraging Pipeline Advancements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXencor Stock Gains 23% on Encouraging Pipeline Advancements\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-11 00:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/xencor-stock-gains-23-encouraging-162200053.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Xencor XNCR gained 23% on Monday after it revealed details on four new programs targeting autoimmune diseases and provided encouraging initial updates on two early-stage oncology programs.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/xencor-stock-gains-23-encouraging-162200053.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1280957306.USD","symbol_name":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","start_time":0,"source_url":"https://finance.yahoo.com/news/xencor-stock-gains-23-encouraging-162200053.html","article_id":"2466746258","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466746258","pubTimestamp":1725985320,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Xencor XNCR gained 23% on Monday after it revealed details on four new programs targeting autoimmune diseases and provided encouraging initial updates on two early-stage oncology programs.The company announced favorable initial results from two early-stage oncology programs.Initial data from an ongoing phase I study showed signs of anti-tumor activity for its investigational ENPP3 x CD3 bispecific antibody XmAb819 in patients with clear cell renal cell carcinoma. Management expects to reach target dose levels by this year’s end and provide a clinical update in first-half 2025.Xencor also expects to reach target dose levels in the ongoing early-stage study on XmAb808 in metastatic castration-resistant prostate cancer by 2024-end and provide a clinical update in first-half 2025.Year to date, Xencor’s shares have lost 6.3% compared with the industry’s 0.7% decline.Some better-ranked stocks in the overall healthcare sector are Bioventus BVS and Fulcrum Therapeutics FULC. Each sto","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","BK4581":"高盛持仓","BK4504":"桥水持仓","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","JNJ":"强生","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4592":"伊斯兰概念","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4139":"生物科技","BVS":"Bioventus Inc.","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4007":"制药","IBD":"Inspire Corporate Bond ETF","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","FULC":"Fulcrum Therapeutics","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4588":"碎股","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","XNCR":"Xencor Inc","BK4198":"医疗保健用品","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H"},"translate_title":"Xencor股价因令人鼓舞的管道进步而上涨23%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XNCR":1,"JNJ":1,"IBD":1,"FULC":1,"BVS":1},"content_text":"Shares of Xencor XNCR gained 23% on Monday after it revealed details on four new programs targeting autoimmune diseases and provided encouraging initial updates on two early-stage oncology programs.\nXencor Shares Favorable Updates on Oncology Pipeline\nThe company announced favorable initial results from two early-stage oncology programs.\nInitial data from an ongoing phase I study showed signs of anti-tumor activity for its investigational ENPP3 x CD3 bispecific antibody XmAb819 in patients with clear cell renal cell carcinoma. Management expects to reach target dose levels by this year’s end and provide a clinical update in first-half 2025.\nXencor also expects to reach target dose levels in the ongoing early-stage study on XmAb808 in metastatic castration-resistant prostate cancer by 2024-end and provide a clinical update in first-half 2025.\nYear to date, Xencor’s shares have lost 6.3% compared with the industry’s 0.7% decline.\nImage Source: Zacks Investment Research\nDetails on Xencor’s New Autoimmune Programs\nXNCR intends to start a phase Ib/IIa study on plamotamab, a CD20 x CD3 bispecific T-cell engager, for multi-drug-resistant rheumatoid arthritis (MDR-RA) in first-half 2025. This advancement is based on positive data from a phase I study that evaluated the drug in hematologic cancers.\nThe company regained the rights to plamotamab after pharma-giant Johnson & Johnson JNJ terminated its right to the drug as part of an ongoing collaboration agreement entered in 2021. Management is developing two drugs, JNJ-9401 and JNJ-1493, as part of its collaboration with J&J in separate early-stage studies for prostate cancer and B-cell tumors, respectively.\nManagement intends to dose the first patient with its novel anti-TL1A antibody XmAb942 in a phase I study for treating inflammatory bowel diseases (IBD) in fourth-quarter 2024. Interim data from this study is expected in the early next year.\nXencor is also preparing to advance XmAb657, a CD19 x CD3 bispecific antibody, to an early-stage study for autoimmune diseases in second-half 2025. The company also intends to move an XmAb bispecific antibody targeting TL1A and IL-23 pathways for IBD in 2026.\nOur Take\nWhile Xencor’s decision to advance four new candidates in the autoimmune disease space seems enthusiastic, we advise investors to exercise caution when making investment decisions based on this factor only. These candidates are still in early-stage development and carry significantly high risks of potential failure. The stock’s near-term prospects are tied to its oncology pipeline, which is expected to report data early next year.\nXNCR’s Zacks Rank\nXencor currently carries a Zacks Rank #3 (Hold).\n\nXencor, Inc. Price\n\nXencor, Inc. price | Xencor, Inc. Quote\n\nOur Key Picks Among Biotech Stocks\nSome better-ranked stocks in the overall healthcare sector are Bioventus BVS and Fulcrum Therapeutics FULC. Each stock presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Bioventus’ 2024 earnings per share (EPS) have risen from 27 cents to 40 cents. Estimates for 2025 EPS have increased from 43 cents to 45 cents during the same period. Year to date, shares of Bioventus have surged 99.2%.\nBVS’ earnings beat estimates in three of the last four quarters and missed the mark on one occasion. Bioventus delivered a four-quarter average earnings surprise of 102.86%.\nIn the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have improved from $1.24 to 48 cents. Estimates for 2025 loss per share have improved from $1.71 to $1.51 during the same period. Year to date, Fulcrum Therapeutics’ shares have rallied 27.9%.\nEarnings of Fulcrum Therapeutics beat estimates in each of the last four quarters. Fulcrum Therapeutics delivered a four-quarter average earnings surprise of 393.18%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nJohnson & Johnson (JNJ) : Free Stock Analysis Report\nXencor, Inc. (XNCR) : Free Stock Analysis Report\nFulcrum Therapeutics, Inc. (FULC) : Free Stock Analysis Report\nBioventus Inc. (BVS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466746258"}